Proteon Therapeutics, Inc.

If you purchased Proteon Therapeutics, Inc. securities and would like to join the action, please click "Join This Action" below.

PROTEON MERGER INVESTIGATION: HALPER SADEH LLP ANNOUNCES INVESTIGATION INTO WHETHER THE SALE OF PROTEON THERAPEUTICS, INC. IS FAIR TO SHAREHOLDERS; INVESTORS ARE ENCOURAGED TO CONTACT THE FIRM – PRTO

September 23, 2019.

New York, New York—Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger between Proteon Therapeutics, Inc. (NASDAQ: PRTO) and ArTara Therapeutics, Inc. (“ArTara”) in an all-stock transaction is fair to Proteon shareholders. On behalf of Proteon shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

The Proteon merger investigation concerns whether Proteon and its Board of Directors violated the federal securities laws and/or their fiduciary duties to shareholders by failing to: (1) obtain the best possible consideration for Proteon shareholders; and (2) disclose all material information necessary for Proteon shareholders to adequately assess and value the merger consideration.

Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Certification

Scroll to Top